8 ms·
Before you assume that LDL isn’t a good biomarker, read the entire article. Specifically this section: > Why? In some ways, cholesterol has become a victim of
by Aurornis 1y ago
Before you assume that LDL isn’t a good biomarker, read the entire article. Specifically this section:
> Why? In some ways, cholesterol has become a victim of its own success. We now screen the whole population for high cholesterol, give statins to those with high LDL (or ApoB), and so then the majority of people who end up having heart attacks have lower cholesterol than they would naturally have
In other words, in the study population patients who would have had high LDL were likely to be on statins. The had a lower measured LDL value even though they might still be consuming a poor diet and living an unhealthy lifestyle, for example. Statins don't fix everything about poor diet and lifestyle, but they do help with cholesterol.
So don’t go throwing LDL out yet. It’s still the best measure we have, though you should obviously know that LDL measured while on statins is lower than it would be normally.
The headline, therefore, is somewhat clickbait from a company trying to sell these tests to you outside of your insurance. I recommend checking your insurance to see if the tests would be covered before you go the self-pay route.
Edit to add: If your doctor won't order hs-CRP for some reason, you can order it from sites like privatemdlabs.com for $50 (less if you take their 25% off coupon).
- FollowingTheDao 1y agoYes, LDL is the best we have since they won’t bother to measure oxidative stress nor inflammation in the human body. But lowering your LDL does not prevent heart disease. There are many many people with normal LDL who have heart attacks. In fact, it is the norm. And I can’t imagine how many people are being told. They have no heart disease risk just because their LDL is normal. It’s a crime and it needs to be stopped. https://www.uclahealth.org/news/release/most-heart-attack-patients-cholesterol-levels-did-not-indicate-cardiac-risk https://www.uclahealth.org/news/release/most-heart-attack-pa... A new national study has shown that nearly 75 percent of patients hospitalized for a heart attack had cholesterol levels that would indicate they were not at high risk for a cardiovascular event, based on current national cholesterol guidelines.
- p1esk 1y agoHow can inflammation be measured?
- hirvi74 1y agoI am sure there are other means, but I always thought C-Reactive Protein levels were the standard measure.
- Aurornis 1y ago> But lowering your LDL does not prevent heart disease. There are many many people with normal LDL who have heart attacks. Wearing a seatbelt does not prevent death in a car accident. There are many people who wear seatbelts who still perish in car accidents. While you can find a vocal minority who claim cholesterol is not related to heart disease, the best evidence we have is that it is. A lot of the doctors pushing cholesterol denialism are into quacks, such as Uffe Ravnskov who pivoted from denying a link between LDL and CVD into preaching Vitamin C to treat COVID when that hit the news. However, it's not the only actor in determining heart attack risk.
- imtringued 1y agoLowering LDL isn't equivalent to a seatbelt. A seatbelt is a safety device that performs a function in an accident. LDL is used as a predictor because it is easy to measure not because LDL itself causes heart disease. Lowering LDL doesn't actually do anything on its own, because it is just a proxy metric for the underlying problem. It's more cranky to shutdown discussions by misrepresenting someone's position as "cholesterol denialism". What does that even mean in this context? Finding better predictors is denialism. Great now we just need a ministry of truth.
- llm_nerd 1y ago>Lowering LDL doesn't actually do anything on its own Is this some sort of weird philosophical statement? Because, of course, it's completely nonsensical, and completely at odds with all data on this file. Lowering LDL reduces CVD incident rates, with no other interventions. People with genetically low LDL also have lower CVD incident rates. This is extraordinarily well proven. So it sure seems -- you know, 100% of medical science -- that lowering LDL does "something". The human body is a complex machine, however, and CVD is multifactorial, and for CVD to develop the current thinking is that you need inflammation and high cholesterol over decades. Inflammation can be caused by things like high blood pressure and the like. But everyone has inflammation to some degree as a facet of living, and the easiest component of that to treat (not just measure) is LDL. And yes, there is an industry of cholesterol denialists, among whom there are just loads and loads of chiropractors. These clowns have built armies of poorly informed disciples that run to HN to tell us that cholesterol doesn't matter and lowering LDL doesn't do anything.
- cthalupa 1y agoLowering LDL is one of the best preventative measures we have for ASCVD. https://www.lipidjournal.com/article/S1933-2874%2825%2900317-4/fulltext https://www.lipidjournal.com/article/S1933-2874%2825%2900317... That people can still experience a heat attack even with low LDL does not change that fact. We have very large studies showing the efficacy of lowering LDL.
- llm_nerd 1y ago>But lowering your LDL does not prevent heart disease Literally one of the most proven truths in medical science is that LDL levels has an almost directly relationship with CVD risk over the long term. Someone with low cholesterol can of course still have CVD, but their odds are much better than someone with high cholesterol. And of course the damage from cholesterol is additive, so the earlier you control LDL, the more of a benefit. >A new national study has shown that nearly 75 percent of patients hospitalized for a heart attack had cholesterol levels that would indicate they were not at high risk for a cardiovascular event, based on current national cholesterol guidelines. The damage from high cholesterol happens over decades. Yet the people who actually have heart attacks are often older. So yes, if gramps spent his life with high cholesterol but now he barely eats and is sedentary, he might have low cholesterol now but that says literally nothing to what you're claiming it does.
- imtringued 1y ago[flagged]
- llm_nerd 1y agoYou have left multiple comments for the sole purpose of muddying waters. So HN would probably be better off if you didn't reply. What did I "shout"? What are you even going off about? Don't project your angry fanaticism on others. Further, your literacy is not my problem. Nothing in my comment was contradictory or confusing to anyone but you.
- cthalupa 1y agoNo. They’re saying that damage is cumulative over a lifetime - plaque deposition - so that a point in time snapshot of LDL says little about lifetime exposure. If I live my life with high LDL and only get on statins at 65 I might have low LDL when I have a heart attack but the damage came from the decades of high LDL. The current guidance from the AHA and NLA is that lower is better for as long as possible.
- FollowingTheDao 1y agoLower cholesterol helps but lowering inflammation helps everyone. As I’ve said in another comment over 75% of people who have heart attacks have normal LDL levels. https://www.uclahealth.org/news/release/most-heart-attack-patients-cholesterol-levels-did-not-indicate-cardiac-risk https://www.uclahealth.org/news/release/most-heart-attack-pa... And lower cholesterol is not without its own risks. You need cholesterol to make hormones and things like CoQ10, which are important for our health. So what’s better? Lowering oxidative stress and inflammation or lowering cholesterol?
- deleted 1y ago[deleted]
- brandonb 1y ago(OP here) LDL is still a good biomarker, but ApoB is a better biomarker for the same undelrying risk factor -- each atherogenic particle (LDL, VLDL, IDL) has exactly one ApoB molecule. The reason we offer the tests as cash pay is that it's the only way we can guarantee the price. In the past, when we've gone through insurance, the insurer's "negotiated rate" for the same exact panel comes out to $1,400-$1,500. If the insurer later decides to deny coverage for any of the tests, it's more expensive for the patient. The $190 price is negotiated to be pretty low. It includes hs-CRP ($59 by itself online), but also the other major heart health biomarkers: ApoB ($69), Lp(a) ($49), A1c ($39), lipid panel ($59), eGFR ($99), other biomarkers, and a video consultation with a doctor to actually explain the results and what to do about them. For hs-CRP in particular, it's not covered under the ACA as a preventive benefit, so you would usually need to hit your deductible before insurance kicks in at all. (That's assuming they count it as medically necessary at all -- for example, Aetna's current medical policy for hs-CRP requires 2 risk factors, LDL in a specific range, and overall cardiovascular risk to be in a certain range or the claim would simply be denied). It's possible this will change over time as the ACC/AHA recommend universal screening, and I hope it does, but it's a relatively a slow process since it depends on the US Preventive Services Task Force to issue a formal recommendation.
- Aurornis 1y agoFYI the above poster is the founder of the company selling these tests (EDIT: He edited his comment to include the "OP here" intro after I posted my comment. Thanks!) > In the past, when we've gone through insurance, the insurer's "negotiated rate" for the same exact panel comes out to $1,400-$1,500. hs-CRP is not going to be a $1500 negotiated rate under any insurance these days. No sane insurance company is going to pay that. I understand that the negotiated rate you're talking about is for an entire panel of many markers, but most of these are not necessary for a quick screen and many would already be covered by an ACA annual checkup. > It includes hs-CRP ($59 by itself online), hs-CRP is $50 right now at privatemdlabs.com before the 25% off coupon they're blasting me with in the pop-up. It appears to be in the $40-45 range at a few other direct lab companies.
- brandonb 1y ago
- bluGill 1y agoThere have always been people with high LDL who lived to a very old age and finally died of something other than a heart attack (nobody knows why). Still high LDL after controlling for everything we can think of (cholesterol is cheap to measure so we have a lot of data!) is a strong sign of a future heart attack and so anyone with high LDL should talk to their doctor: there is good reason to think statins will reduce your chance of a heart attack. Which why we measure it and control it. If you have normal cholesterol though - we have long known that people with normal cholesterol also have heart attacks. It isn't as common as people who have high cholesterol, but it is still very common for someone normal cholesterol to have a heart attack. We don't really know what to do about this though. This article is saying we should measure inflammation and if found deal with it. Seems reasonable. What isn't known is if we deal with inflammation will heart attacks go away or if there are more factors. If there are more factors we don't know what they are or if they are worth measuring/treating (though some researchers may have data they are trying to get out here). If dealing with inflammation is good, can we start ignoring cholesterol - another unknown (one for researchers to look into, but the rest of us should for now say no cholesterol is independently important - until data says otherwise)
- Aurornis 1y agoLDL is a proxy measure that's cheap and easy to measure. It's widely used for screening despite not being perfect, which confused some into thinking it's the one and only thing measure of CVD risk. It's not, though. Many of the tests we look at are proxies and markers, not actually the sole factor for a disease. More in-depth testing would check LDL-P (particle count) and ApoB along with hsCRP. Though realistically, most people could simply look at their diet and lifestyle and work on improving both before investing in any extra testing. The testing can be useful to catch cases where genetics overwhelm even healthy lifestyles, but in many cases for younger people the testing basically serves as a wake-up call to actually do something about lifestyle and diet problems. It's easier to inspire lifestyle and diet changes when you're staring at bad numbers on the test results and getting a little preview of the consequences of your decisions.
- Maxion 1y ago
- goalieca 1y agoBut if they have lower cholesterol and still have a heart attack, then certainly the causal link is not quite there. It seems you’re suggesting it’s a good proxy measurement if untampered by statins though
- hombre_fatal 1y agoStatins are generally administered after decades of exposure to high cholesterol/ApoB. Decades of plaque accumulation doesn't just go away when you lower your cholesterol. The question is if people who keep their cholesterol/ApoB low (e.g. Mendellian randomization) have better health outcomes, and the evidence is clear. Lifelong exposure to cholesterol/ApoB mediates atherosclerosis.
- PantaloonFlames 1y ago> Lifelong exposure to cholesterol/ApoB mediates atherosclerosis I would normally interpret that to mean, lifelong elevated levels of cholesterol/ApoB _decreases_ atherosclerosis. Is that what you meant?
- deleted 1y ago[deleted]
- mikeyouse 1y agoIn medicine, “mediates” is mostly synonymous with “facilitates”. So ‘lifelong exposure to cholesterol facilitates atherosclerosis’ - mediates is a bit softer since health changes often involve multiple pathways and can be impacted by many other processes.
- lazyasciiart 1y agoI personally have naturally very low cholesterol and also had a heart attack in my 30s. There are a handful of case studies published of other people in this scenario but it is a rare enough scenario, and it is vanishingly rare to have years of reliable cholesterol results without known high risk.
- 1y ago
- HumblyTossed 1y agoIf you're already on statins, they may be lowering your hs-CRP. Still have that conversation with your dr.
- Alex3917 1y ago> It’s still the best measure we have, though you should obviously know that LDL measured while on statins is lower than it would be normally. I'm not a doctor, but doesn't LDL basically just prevent the body from healing damage to the epithelium, which comes from things like high blood pressure and inflammation? Unless my understanding is wildly off base, it doesn't really make sense that a thing that merely slows down the healing process would be more predictive than the things causing the damage in the first place, given that if you aren't accumulating significant damage then your levels of cholesterol are somewhat moot.
- brandonb 1y agoMy favorite definition of heart disease is "when circulating fats in the blood (lipids) are pushed by a driving force (blood pressure) into a vessel wall that is vulnerable (endothelial dysfunction)." IMO this gives a good mental picture of how all of these risk factors fit together.
- orochimaaru 1y agoThere is a detailed lipid panel (Lipofraction NMR) as along with the HDL/LDL/TriG estimates they get today. There is a lot more detail in there. Statins help reduce LDL but the detailed lipid panel may still show a very high level of LDL-P and Small LDL-P which still increase risk. If you're going for more testing, I would definitely suggest the lipofraction.
- brandonb 1y agoThe most recent evidence is that if you’re measuring ApoB and Lp(a), you’re capturing the same information as fractionation (with the bonus that the former two are slightly faster and cheaper at most commercial labs): https://academic.oup.com/eurheartj/article-abstract/46/27/2702/8125560?redirectedFrom=fulltext https://academic.oup.com/eurheartj/article-abstract/46/27/27...
- makeitdouble 1y agoLDL levels is too complex to be used as the litmus test it has become. This might dependent on how much you care about false positives and pushing wrong advice to people, but the difference in levels in non Caucasian ethnies in particular is kind of ignored in most directives. When looking deeper into it, it's a lot more complex than a simple "higher than X is market for Y". For instance: https://www.ahajournals.org/doi/10.1161/01.atv.19.9.2234 https://www.ahajournals.org/doi/10.1161/01.atv.19.9.2234 > In conclusion, we have found an ethnic difference in the LDL size distribution, with African Americans having the highest LDL size (“less atherogenic”) and Hispanics having the lowest LDL size; these ethnic differences in LDL size, however, appear to be primarily due to differences in triglyceride and HDL cholesterol among the ethnic groups. Similar variables (triglyceride, HDL cholesterol, insulin resistance, etc) appear to be related to LDL size in these ethnic groups. Last, ethnic differences in LDL size are not consistent with previously reported differences in their risk of CVD or atherosclerosis; in fact, the ethnic differences in LDL size may be opposite the CVD risk differences by ethnic group.
- KempyKolibri 1y agoDiscordances like this between LDL-c and ApoB are one of the reasons many lipidologists are pushing for LDL-c measurement to be replaced with ApoB.
- simianparrot 1y agoThe problem I'm seeing here in Norway is that the bar to put people on statins is way too low given the severe side-effects and likely consequences of long-term statin use, even low doses. I think LDL is a good biomarker, just not in isolation, and especially not a "one-size fits all" metric for individual humans.
- DrAwdeOccarim 1y agoI’m surprised by your strong wording. >”… severe side-effects and likely consequences of long-term statin use, even low doses.” Could you provide a few reputable clinical outcomes studies to support your statements? I was unaware of these risks.
- simianparrot 1y agoFor one: https://pmc.ncbi.nlm.nih.gov/articles/PMC2949584/ https://pmc.ncbi.nlm.nih.gov/articles/PMC2949584/ These drugs require constant monitoring by physicians that understand what to look for, that are actively involved in adjusting dosage, for them to be even remotely safe. Muscle atrophy is considered an "uncommon side-effect", but that's just because most studies aren't performed over long enough periods of time. People tend to be kept on statins permanently. And that changes the safety factor considerably, as it does with any medicine taken over years. My anecdotal evidence is based on multiple family members on these drugs and how even in Norway, with our fairly good healthcare system, it's not monitored sufficiently to avoid issues. There's a lot of strong feelings around statins as is apparent in the other response to my comment, but claims about them being safe except in outlier cases is simply not true.
- cthalupa 1y agoThe numbers suggested in this article (and to be clear, what you have linked is not a study - it is a discussion by graduate students in a PT/exercise science program. Not to disparage them, but this is not primary research) do not match the results we see in actual RCTs or meta analysis of them. See the bottom half of my comment at https://news.ycombinator.com/item?id=45446913 https://news.ycombinator.com/item?id=45446913 - significant muscle damage is exceedingly rare, and ~90% of the muscle pain reported in the RCTs ended up not being related to the statins at all. Your claims are simply not backed by the data. These are some of the most prescribed and studied drugs on the planet.
- meindnoch 1y agowhen a measure becomes a target etc etc
- cthalupa 1y agoLDL has always been both a worthwhile measure and target. It's not perfect as a measure - it doesn't account for Lp(a), for example, and why ApoB is a better indicator for the atherogenic particles portion of the equation - but we know that lowering LDL lowers the risks of ASCVD and results in better health outcomes. I've linked quite a few studies over the comments here backing this up with huge quantities of data points.
- reverendjames 1y agoApoB is the best measure we have.
- sonicggg 1y agoYou forgot to mention that statins are an anti-inflammatory as well. This argument itself fails on that
- cthalupa 1y agoPCSK9 inhibitors do not universally lower hsCRP but still reduce cardiovascular events. https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4876179/ https://pubmed.ncbi.nlm.nih.gov/36779348/ https://pubmed.ncbi.nlm.nih.gov/36779348/ MR studies on genetics show that LDL and Lp(a) are independent risk factors for cardiovascular events regardless of hsCRP https://www.nejm.org/doi/full/10.1056/NEJMoa1109034 https://www.nejm.org/doi/full/10.1056/NEJMoa1109034 https://pmc.ncbi.nlm.nih.gov/articles/PMC5483508/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5483508/ https://europepmc.org/article/med/20032323 https://europepmc.org/article/med/20032323 https://journals.plos.org/plosmedicine/article%3Fid%3D10.1371/journal.pmed.1003062 https://journals.plos.org/plosmedicine/article%3Fid%3D10.137... https://www.nejm.org/doi/full/10.1056/NEJMoa1604304 https://www.nejm.org/doi/full/10.1056/NEJMoa1604304 https://pubmed.ncbi.nlm.nih.gov/23083789/ https://pubmed.ncbi.nlm.nih.gov/23083789/
- naveen99 1y agoLDL has a u shaped association with mortality , just like bmi. Statins have a lot of side effects also, lots of muscle toxicity.
- cthalupa 1y agoLDL and BMI's u and j shaped curves on all cause mortality disappear when you start controlling for other factors like a variety of diseases. Cancer, kidney disease, AIDS, etc. Lots of people end up with very poor nutrition when close to death from these diseases and end up with low bf%/bmi and LDL levels. The reputation for bad side effects with statins is basically entirely driven by early generation statins - we've got many that are far better suited for use today than things like lovastatin and similar. Rosuvastatin, pitavastatin, etc. are much less likely to cause any sort of issue for the vast majority of people. Most of the side effects come at higher dosages, too, but most of the benefit comes from lower dosages. Combo therapy with lower dose statin + ezetimibe or bempadoic acid is becoming more and more popular for this reason.
- naveen99 1y agothe number needed to treat for a benefit from statins is high and the absolute risk reduction small.
- cthalupa 1y agoPlease stop spreading misinformation about life-saving medication. This is simply untrue. https://www.lipidjournal.com/article/S1933-2874(25)00317-4/fulltext https://www.lipidjournal.com/article/S1933-2874(25)00317-4/f... > Based on the Cholesterol Treatment Trialists Collaboration meta-analysis of 27 statin RCT’s (statin vs placebo and high intensity vs moderate intensity statin), for every 1 mmol/L (∼39 mg/dL) reduction in LDL-C there is a corresponding 22% reduction in ASCVD event risk Even people with "normal" LDL levels see reduction in risk. And people with high LDL levels might end up with a 3-4 nmol/L (or more!) reduction with combo therapy. Meanwhile statins are widely available, very cheap even without insurance, and as previously noted, have excellent side effect/safety/efficacy profiles for modern generations. Your inaccurate information may be dissuading people who would otherwise get on these medications from doing so when it could literally be the difference between them living and dying. It's irresponsible.
- martin82 1y agoIt should be extremely easy to take this into consideration, and create cohorts of people who were not on a statin. I'm quite sure we would still see that cholesterol is useless and that inflammation drives everything.
- cthalupa 1y agoWe have all sorts of RCTs, blinded studies, placebo controlled studies, MR studies that look at genetics, meta-analysis, etc. etc. etc. that all support the causal link of cholesterol... I've linked literally dozens of these in the comments for this article. If you care, feel free to look at my recent comment history - it's all in there and all my claims sourced. The OVERWHELMING evidence is that cholesterol is a hugely important causal factor. Overwhelming to the point that we can't do controlled trials for people with CVD risk with cohorts not on a statin in this day and age - it wouldn't pass ethical review, because we have so much data. It is not ethical to withhold lifesaving medication from people when we know it is lifesaving.
- Centigonal 1y ago> In other words, in the study population patients who would have had high LDL were likely to be on statins. The had a lower measured LDL value even though they might still be consuming a poor diet and living an unhealthy lifestyle, for example. Statins don't fix everything about poor diet and lifestyle, but they do help with cholesterol. The implication here is that the LDL-lowering effect of statins is greater than the CVE-reducing effect of statins. That is, if the statins lower your LDL by 30%, that doesn't bring your risk of heart disease the to the same level as someone who naturally has an identical lower LDL.
- cthalupa 1y agoFor sure. Someone who naturally has the lower LDL is more likely to have had that lower LDL for longer - being on statins necessarily indicates they had a high LDL at some point, and the damage is cumulative over your lifetime. If you blocked your arteries before you got on a statin, it can stabilize the plaque and reduce the risk of rupture, reduce the ability for more to form and increase the blockage, and if it gets your LDL low enough, regress some of it, but it's not going to give you the same arteries as someone who never had that level of plaque deposition to begin with.